BPC-157: Where the Evidence Runs Out — 175 Papers, 31 Human Subjects, One Abandoned Trial

BPC-157 has one of the largest preclinical literatures of any research peptide and almost no human data. Both are true at once. The gap has a precise location: a Phase 1 trial registered in 2015 that never reported a result.

That single fact organises everything else on this page. This article works from the primary literature rather than restating either half of the usual story — where the corpus comes from, what the animal work does and does not show, the three human studies in full, the registered trial that vanished, what the July 2026 FDA advisory vote did and did not do, and which widely repeated claims survive a sequence check. Compound identity sits on the BPC-157 compound page, inside the tissue repair and healing peptides category.

Why does almost all BPC-157 research come from one laboratory?

A PubMed search for Predrag Sikirić combined with "BPC 157" returns 175 records, and the overwhelming majority of BPC-157 research traces to a single group: the Department of Pharmacology at the University of Zagreb, where the peptide was characterised in the 1990s. Single-source concentration is not disqualifying, and plenty of legitimate compounds began this way. It does mean the usual correction mechanism — independent groups attempting a finding, failing, and publishing the failure — has largely not operated here.

Two 2025 reviews show the split cleanly. The Zagreb group's own synthesis, "Stable Gastric Pentadecapeptide BPC 157 as a Therapy and Safety Key" (Pharmaceuticals), states that BPC-157 "controls angiogenesis and the NO-system's healing functions" and claims "high safety (LD1 not achieved)."

An independent Polish review published months earlier in the same journal, "Multifunctionality and Possible Medical Application of the BPC 157 Peptide", concluded that BPC-157 "has not been approved for use in standard medicine by the FDA and other global regulatory authorities due to the absence of sufficient and comprehensive clinical studies," and noted that "not all studies conducted on animals can always be freely transferred to humans." The Zagreb group published a formal rebuttal to it.

That disagreement, in print, between the originating group and independent reviewers is the honest state of the field. It is not a scandal. It is what an unresolved literature looks like.

What is BPC-157, and what does its name get wrong?

BPC-157 is a synthetic 15-amino-acid fragment of Body Protection Compound, a protein isolated from gastric juice, with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. It carries CAS 137525-51-0, a molecular weight of 1419.5 g/mol, and a half-life under 30 minutes with hepatic metabolism and renal clearance. It has no identified dedicated receptor. The "stable gastric" label describes resistance to stomach acid, not shelf stability in a vial.

The phrase "stable gastric pentadecapeptide" runs through the entire literature and is routinely read as a claim about the product. It is not. It refers to the molecule's resistance to degradation in stomach acid, which is a biological property of the sequence. Shelf stability in a reconstituted vial is a separate question, and one nobody has published on.

Keep the sequence visible. It settles a claim several sections below that a great deal of storage advice rests on.

What has BPC-157 actually shown in animals?

The animal record is broad and, within its limits, consistent, and the proposed mechanism is multi-pathway rather than single-receptor. The 2025 independent scoping review "Regeneration or Risk?" (Current Reviews in Musculoskeletal Medicine) describes activation of "VEGFR2 and nitric oxide synthesis via the Akt-eNOS axis, promoting angiogenesis, fibroblast activity, and neuromuscular stabilization," plus ERK1/2 signalling. The most rigorous accounting of the corpus screened 544 articles and included 36 — 35 preclinical, one clinical.

Two studies reward reading directly rather than through summaries.

In cultured rat Achilles tendon fibroblasts, BPC-157 increased growth hormone receptor expression, and adding growth hormone to treated cells produced dose- and time-dependent proliferation (Molecules, 2014). The authors concluded this "may potentiate the proliferation-promoting effect of growth hormone and contribute to the healing of tendon." That is a mechanism proposal from cell culture, and it is frequently cited as though it were a tendon-healing result in a living animal, let alone a person.

In a rat medial collateral ligament transection model with 90-day follow-up, BPC-157 given intraperitoneally at 10 µg or 10 ng/kg, applied locally, or given orally produced "consistent functional, biomechanical, macroscopic and histological healing improvements" (Journal of Orthopaedic Research, 2010). This is a well-conducted animal study and the strongest single piece of tendon-and-ligament evidence in the corpus.

The 35:1 ratio comes from the 2025 systematic review in HSS Journal, "Emerging Use of BPC-157 in Orthopaedic Sports Medicine", whose own limitations paragraph describes the evidence base as "level IV and level V studies."

How many people have taken BPC-157 in a published study?

Three published human studies of BPC-157 exist, involving about 31 subjects in total. All three appeared in the same journal and share the same lead author. None is randomised. None has a control or placebo arm. None is blinded. Outcomes were captured by telephone follow-up or a global assessment score rather than a validated instrument — the design most vulnerable to expectation effects, in conditions where placebo response rates are high.

The intravenous study is routinely described as establishing safety and pharmacokinetics. It enrolled two people who had both used BPC-157 previously, observed them for three days, and reported no pharmacokinetic curve.

There is also a discrepancy worth naming. The HSS Journal systematic review characterises the knee study as "7 of 12 patients reported relief for >6 months," while the primary paper reports 11 of 12 with "significant improvement." Those are different endpoints — durability versus any improvement — and the gap shows how quickly a modest finding drifts as it is passed along.

No human trial has studied oral BPC-157. Every documented human route is parenteral or local: intra-articular, intravesical, intravenous. The oral evidence is entirely rodent, which is the whole subject of BPC-157 oral vs injectable.

What happened to the only registered BPC-157 trial?

One registered clinical trial of BPC-157 exists, and it never reported. NCT02637284 is a Phase 1 study of PCO-02 (Bepecin) in healthy volunteers, sponsored by PharmaCotherapia d.o.o., with an estimated enrolment of 42. It began in October 2015 with primary completion estimated for February 2016. Its status is Unknown, last recorded as active and not recruiting. No results have been posted and no publication has appeared.

A decade on, the independent Polish review refers to it as an "abandoned Phase I trial."

This matters more than its size suggests, and it is the precise point where the BPC-157 evidence base stops. A completed and published Phase 1 would have given the field human pharmacokinetics — absorption, half-life in people, dose proportionality. That is the largest single gap in the corpus, and it is why every dosing protocol in circulation is built on rodent data and community convention rather than measurement.

Note what this is not. It is not evidence that BPC-157 failed a trial, because no result was published in either direction. It is an absence, and the honest description of an absence is that it is an absence.

What did the July 2026 FDA advisory vote actually change?

Legally, nothing. BPC-157 was removed from the FDA's 503A Category 2 "do not compound" list in April 2026, and at the Pharmacy Compounding Advisory Committee meeting of 23–24 July 2026 the committee voted 8–6 with one abstention to recommend BPC-157 for inclusion on the 503A bulks list. That vote is advisory and non-binding. FDA must complete formal rulemaking first, a process projected for 2027 or later, and the agency is not required to follow the recommendation.

Nothing has been added to the list. Compounding BPC-157 is not authorised by that vote. This is the most misread item in current BPC-157 coverage, and the misreading runs in a predictable direction — a narrow procedural step reported as an approval.

BPC-157 remains prohibited at all times on the WADA Prohibited List under S0 (Non-Approved Substances), and appears on the Department of Defense prohibited ingredients list. The DoD's Operation Supplement Safety states it plainly: BPC-157 "is not a dietary ingredient. It is an unapproved drug and cannot be legally prescribed or sold over the counter," and "there is little to no reliable scientific evidence to support the safety or effectiveness of BPC-157 in humans."

For the full sequence of determinations, see our FDA peptide regulation timeline.

Does BPC-157 need special storage handling to prevent oxidation?

Not for the reason usually given. A large amount of BPC-157 storage advice rests on the claim that the peptide is vulnerable to methionine oxidation, and the sequence contains no methionine. It also contains no cysteine, no tryptophan and no tyrosine — none of the classically oxidation-labile residues. Any vendor page building a handling protocol on methionine oxidation is describing a residue this molecule does not contain.

Read the sequence again:

Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val

The sequence is independently confirmed in Gwyer et al. (Cell and Tissue Research, 2019) and matches the PubChem record.

What is genuinely true is less convenient than the claim it replaces: no peer-reviewed stability or storage study of BPC-157 has been published. Every shelf-life figure in circulation is vendor-derived. General handling practice still applies — see how to store peptides and does shaking damage peptides — but nobody can cite a degradation curve for this compound.

Is pentadeca arginate a better version of BPC-157?

No published evidence supports that. Pentadeca arginate is marketed as an arginine-salt form of BPC-157 with better stability and absorption, frequently with a "90% bioavailability" figure attached, and a PubMed search for "pentadeca arginate" returns zero results. No peer-reviewed publication establishes its identity, pharmacokinetics, bioavailability, stability advantage or equivalence. Every source describing it is a vendor, clinic or telehealth page.

Two chemistry points sit alongside that. An arginate salt is a counter-ion pairing, not a sequence change — it does not alter the peptide. And BPC-157's sequence contains no arginine of its own, so the name describes what has been added to the molecule rather than what the molecule is.

The pentadeca arginate compound page tracks it. The evidence base for the differentiating claims is currently empty, which is a different statement from saying the compound does not exist or does not work — nobody has looked.

Which BPC-157 claims survive the evidence?

BPC-157's tissue-repair and gut claims survive as animal findings and go no further, because no human musculoskeletal or gastrointestinal trial exists. The growth hormone receptor result is real but in vitro. Oral use, systemic dosing and long-term safety are unestablished in humans. Two widely repeated claims fail outright: the methionine-oxidation storage rationale is false, and pentadeca arginate's superiority is a vendor claim with zero literature.

How do you verify a BPC-157 vial before you buy it?

Four checks cover it: mass spectrometry for identity at a mass near 1419.5 Da, HPLC for purity, a net peptide content or amino acid analysis figure for quantity, and an LAL endotoxin result for injectable material. The one thing HPLC purity cannot do is confirm identity — it reports what proportion of the contents is a single species, not which species. Since the clinical questions are unresolved, these are the questions that can actually be answered.

Purity and quantity are separate axes. A 99% pure vial can be substantially underfilled, which is why net peptide content deserves as much attention as the purity number. The general framework is in how to verify peptide quality before you buy, and the compound-specific walkthrough in where to buy BPC-157.

There is a documented precedent for why this is not paranoia. Research-grade custom peptides from two independent commercial suppliers were found to carry contaminating peptides at roughly 1% by weight — enough to produce false-positive results in immunology assays, with a correlation of r²=0.90 between responses to the contaminated peptide and to the contaminant (Clinical and Vaccine Immunology, 2008). That study concerned HIV vaccine peptide libraries rather than BPC-157, but it establishes that reputable suppliers ship contaminated material at levels that change outcomes.

What does Peptigrity's own BPC-157 testing data show?

Peptigrity's Purity Index records a BPC-157 purity index of 99.37 across 588 recency-weighted tests from 23 laboratories (verified August 2026), against a platform composite of 99.50. The compound page shows 805 total HPLC tests averaging 99.35% across 230 verified shops (verified August 2026). The larger figure is larger because the index applies recency weighting and excludes blend vials and net-content-only tests.

Both carry the same caveat, and it is worth stating rather than burying: these are certificates that vendors chose to publish, which is a selection-biased sample rather than a random market survey. It remains the largest analytical dataset on BPC-157 that exists, because there is no published product-testing study to compare it against.

On price, BPC-157 price data shows 66 shops in stock, a median of $5.90/mg and a lowest tracked price of $1.50/mg on a 10 mg vial (verified August 2026). Those figures exclude shipping, taxes and customs, coupon codes, bulk tiers, multi-vial kits and account-gated pricing. The lowest figure is the lowest of tracked sources, not the lowest payable.

Frequently Asked Questions

Does BPC-157 work?

In animals, consistently and across many tissue types. In humans, nobody knows — the entire human record is three uncontrolled pilot studies totalling about 31 subjects, with no randomised trial of any indication.

Is BPC-157 legal now that the FDA advisory committee backed it?

No. The July 2026 vote was a non-binding recommendation, carried 8–6 with one abstention. FDA must complete rulemaking before BPC-157 could be legally compounded, projected for 2027 or later. It remains an unapproved drug and is prohibited in sport at all times under WADA's S0 category.

Does oral BPC-157 work?

No human study has tested it. Rodent studies show oral dosing produces effects, and the peptide is genuinely acid-stable — but stability in the stomach is not the same as absorption into circulation. See BPC-157 oral vs injectable.

Does BPC-157 cause cancer?

There is no evidence that it does and no evidence that it doesn't. The theoretical concern follows from the mechanism: a compound that promotes new blood vessel formation warrants caution in anyone with an existing or suspected malignancy, because that is also how tumours grow. No human study has examined it.

Do I need to worry about oxidation when storing it?

Not for the reason usually given — BPC-157 contains no methionine, cysteine, tryptophan or tyrosine. Handle it as you would any lyophilised peptide, but be aware that no published stability study for this compound exists.

How do I know the vial is really BPC-157?

Mass spectrometry showing a mass near 1419.5 Da. HPLC purity alone cannot confirm identity — it only tells you what proportion of the contents is a single species, not which species it is.

The trial that would settle this

The trial that would settle BPC-157 is randomised, double-blind and placebo-controlled in a single defined indication, because the three existing studies have none of those features and span three unrelated conditions. It samples pharmacokinetics, since no human PK data exists at all. It uses a validated instrument with imaging rather than telephone-reported improvement, and it runs long enough to separate healing from natural history.

Until something like that reports, the independent reviewers' conclusion stands. As the 2025 Current Reviews in Musculoskeletal Medicine scoping review put it: "Until well-designed clinical trials are conducted, BPC-157 should be considered investigational, and its use approached with caution."

Where this leaves BPC-157

BPC-157 is a compound with unusually strong animal data, an unusually weak human record and an unusually concentrated authorship. That combination deserves to be taken seriously in both directions: it is neither the settled healing agent its promoters describe nor the empty claim its harshest critics imply. It is a genuinely promising preclinical compound that has not been tested properly in people, sold in a market where the material itself is unverified by default.

The boundary is nameable, which is rare. It sits at a Phase 1 trial that enrolled healthy volunteers, was estimated to complete in February 2016, and published nothing. Everything downstream of that point — human dosing, human half-life, human safety — is extrapolation.

Browse the tissue repair and healing peptides category, or our complete peptide guide with 118 compounds (verified August 2026). For per-injection volume, use the BPC-157 calculator — or the BPC-157 + TB-500 calculator if you are running both — alongside the reconstitution calculator. Compare shops through independent lab tests, and see what others are reporting in the community forum.

This article is for educational and informational purposes only and does not constitute medical advice. Peptides discussed may be investigational compounds not approved by the FDA (or equivalent regulators in your jurisdiction) for human use. Always consult a qualified healthcare provider before using any peptide or research compound. Peptigrity is an independent review platform and does not sell, endorse, or recommend specific products or vendors.